Insmed Incorporated

DB:IM8N Stock Report

Market Cap: €11.6b

Insmed Future Growth

Future criteria checks 2/6

Insmed is forecast to grow earnings and revenue by 54.6% and 49.4% per annum respectively. EPS is expected to grow by 56% per annum. Return on equity is forecast to be -139% in 3 years.

Key information

54.6%

Earnings growth rate

56.0%

EPS growth rate

Biotechs earnings growth36.2%
Revenue growth rate49.4%
Future return on equity-139.0%
Analyst coverage

Good

Last updated04 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:IM8N - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,035-483-431-25315
12/31/2025523-791-710-69617
12/31/2024356-879-763-71516
9/30/2024343-864-636-619N/A
6/30/2024329-803-591-574N/A
3/31/2024315-747-589-574N/A
12/31/2023305-750-550-536N/A
9/30/2023281-724-524-509N/A
6/30/2023269-696-476-462N/A
3/31/2023257-547-453-442N/A
12/31/2022245-482-410-400N/A
9/30/2022242-434-388-381N/A
6/30/2022221-416-374-367N/A
3/31/2022201-438-348-340N/A
12/31/2021188-435-371-363N/A
9/30/2021174-424-354-346N/A
6/30/2021171-375-336-329N/A
3/31/2021168-319-295-290N/A
12/31/2020164-294-226-219N/A
9/30/2020169-245-215-197N/A
6/30/2020164-242-223-191N/A
3/31/2020151-247-276-235N/A
12/31/2019136-254-293-251N/A
9/30/2019101-293-310-276N/A
6/30/201962-320-311-290N/A
3/31/201932-330-278-264N/A
12/31/201810-324-273-258N/A
9/30/2018N/A-298-248-236N/A
6/30/2018N/A-256N/A-209N/A
3/31/2018N/A-224N/A-190N/A
12/31/2017N/A-193N/A-160N/A
9/30/2017N/A-196N/A-169N/A
6/30/2017N/A-188N/A-162N/A
3/31/2017N/A-180N/A-154N/A
12/31/2016N/A-176N/A-147N/A
9/30/2016N/A-139N/A-116N/A
6/30/2016N/A-132N/A-109N/A
3/31/2016N/A-124N/A-105N/A
12/31/2015N/A-118N/A-101N/A
9/30/2015N/A-105N/A-86N/A
6/30/2015N/A-98N/A-83N/A
3/31/2015N/A-92N/A-77N/A
12/31/2014N/A-79N/A-64N/A
9/30/2014N/A-78N/A-66N/A
6/30/2014N/A-71N/A-61N/A
3/31/2014N/A-57N/A-48N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IM8N is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IM8N is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IM8N is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IM8N's revenue (49.4% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: IM8N's revenue (49.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IM8N is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y